Skip to main content

Clinical trial AG013-ODOM-201

A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy

Organ Tête et Cou
Trial status Trial closed
Trial type
Interventionnal with IMP
Phase Trial phase 2
Academic trial Non
Sponsor Oragenics
EudraCT Identifier 2016-004161-68
Inclusion criteria No prior gene therapy
Last update